[1]郑 玲,张 坤,姚 田.贝伐单抗联合奥沙利铂对耐药卵巢癌患者生存期及血清miR-17-5p、人激肽释放酶10表达的影响[J].陕西医学杂志,2022,51(1):77-80.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.020]
　ZHENG Ling,ZHANG Kun,YAO Tian.Effects of bevacizumab combined with oxaliplatin on survival time and expression of serum miR-17-5p and HK10 in patients with drug-resistant ovarian cancer[J].,2022,51(1):77-80.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.020]
点击复制

贝伐单抗联合奥沙利铂对耐药卵巢癌患者生存期及血清miR-17-5p、人激肽释放酶10表达的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年1期
页码:
77-80
栏目:
药物与临床
出版日期:
2022-01-05

文章信息/Info

Title:
Effects of bevacizumab combined with oxaliplatin on survival time and expression of serum miR-17-5p and HK10 in patients with drug-resistant ovarian cancer
作者:
郑 玲; 张 坤; 姚 田
(西安市人民医院 西安市第四医院妇产科,陕西 西安 710004)
Author(s):
ZHENG Ling; ZHANG Kun; YAO Tian
(Department of Obstetrics and Gynecology,Xi'an People's Hospital,Xi'an 710004,China)
关键词:
贝伐单抗;  奥沙利铂;  耐药卵巢癌;  生存期;  miR-17-5p;  人激肽释放酶10
Keywords:
Bevacizumab;  Oxaliplatin;  Drug-resistant ovarian cancer;  Survival time;  MiR-17-5p;  Human kallikrein 10
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7377.2022.01.020
文献标志码:
A
摘要:
目的:探究了贝伐单抗联合奥沙利铂对耐药卵巢癌患者生存期及血清微小RNA(miR)-17-5p、人激肽释放酶10(HK10)表达的影响。方法:将耐药卵巢癌患者68例,根据治疗方案的不同,分为贝伐单抗组和常规组,各34例。常规组使用奥沙利铂进行治疗,贝伐单抗组联合应用贝伐单抗和奥沙利铂。比较两组的客观缓解率、无进展生存期(PFS)、总生存期(OS)和不良反应发生率。比较两组治疗前后的miR-17-5p、HK10水平。结果:贝伐单抗组的客观缓解率明显高于常规组(P<0.05)。两组的PFS、OS比较经LogRank检验差异具有统计学意义(均P<0.05)。治疗后,两组的miR-17-5p和HK10水平均明显下降,其中贝伐单抗组下降更明显(均P<0.05)。贝伐单抗组高血压、蛋白尿的发生率明显高于常规组(均P<0.05)。结论:贝伐单抗联合奥沙利铂治疗耐药卵巢癌,可有效改善客观缓解率、PFS和OS,降低miR-17-5p和HK10水平,但可增加高血压、蛋白尿的发生风险。
Abstract:
Objective:To investigate the effects of bevacizumab combined with oxaliplatin on the survival time and the expression of serum miR-17-5p and human kallikrein 10(HK10)in patients with drug-resistant ovarian cancer.Methods:A total of 68 patients with drug-resistant ovarian cancer were enrolled.According to different treatment options,they were divided into bevacizumab group and routine group,with 34 cases in each group.The routine group was treated with oxaliplatin,and the bevacizumab group was treated with a combination of bevacizumab and oxaliplatin.The objective remission rate,progression free survival(PFS),overall survival(OS)and incidence of adverse reactions were compared between the two groups.The levels of miR-17-5p and HK10 were compared between the two groups before and after treatment.Results:The objective remission rate of bevacizumab group was significantly higher than that of routine group(P<0.05).The PFS and OS of the two groups were tested by Log-Rank,and the difference was statistically significant(all P<0.05).After treatment,the levels of miR-17-5p and HK10 in the two groups decreased significantly,among which the bevacizumab group decreased more significantly(all P<0.05).The incidence of hypertension and proteinuria in the bevacizumab group was significantly higher than that in the routine group(all P<0.05).Conclusion:Bevacizumab combined with oxaliplatin in the treatment of drug-resistant ovarian cancer can effectively improve the objective remission rate,PFS and OS,and reduce the levels of miR-17-5p and HK10,but increase the risk of hypertension and proteinuria.

参考文献/References:

[1] 钟 亮,刘清壮,蔡茂德.Ⅲ、Ⅳ期上皮性卵巢癌术后腹腔辅助化疗临床观察[J].陕西医学杂志,2020,49(2):193-196.
[2] 王根生,王 悦.卵巢癌微环境与化疗耐药发生相关的研究进展[J].肿瘤,2020,40(1):74-81.
[3] 孙慧霞,郭 哲,许 静.长春酰胺联合奥沙利铂对耐药卵巢癌患者的效果及患者SDF-1因子的影响[J].实用癌症杂志,2019,34(12):2075-2077.
[4] 马小莲,郑德友,何吉庆.贝伐珠单抗注射液联合紫杉醇注射液和顺铂注射液治疗卵巢癌的临床研究[J].中国临床药理学杂志,2018,34(23):2697-2699,2703.
[5] 窦 燕.微小RNA-17-5p及RNA-21在卵巢癌患者血清中的表达及与术后复发的关系[J].中国临床医生杂志,2020,48(5):102-105.
[6] 任晓兵,李 阳,陈广福,等.卵巢癌患者血清HK10、DJ-1的表达及意义[J].山东医药,2019,59(16):16-19.
[7] 李 丹,文 亢,高金宝.贝伐单抗联合奥沙利铂治疗胃癌的疗效观察[J].中国肿瘤临床与康复,2020,27(3):81-84.
[8] 卢淮武,谢玲玲,林仲秋.《2016 NCCN卵巢癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2016,32(8):761-768.
[9] 程海荣,关 慧,陈 杰,等.白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效与安全性分析[J].实用妇产科杂志,2015,31(3):229-232.
[10] 孙红艳,王改华.不同手术方式治疗卵巢癌临床效果及对患者生育功能的影响[J].陕西医学杂志,2019,48(2):79-82.
[11] 李 倩,董 媛,石 妍,等.奥沙利铂联合用药的临床应用与用药安全[J].包头医学院学报,2020,36(4):117-121.
[12] 葛 艳,于 韬,邱 爽,等.贝伐珠单抗联合紫杉醇、奈达铂治疗卵巢癌晚期效果及对血清炎性因子及免疫指标影响[J].中国计划生育学杂志,2020,28(12):2030-2033,2037.
[13] 李 宁,孔北华,尹如铁,等.晚期上皮性卵巢癌一线维持治疗专家共识[J].现代妇产科进展,2019,28(10):721-723.
[14] 李海燕.铂类抗癌药物作用靶点及耐药机制的研究进展[J].天津药学,2018,30(5):62-66.
[15] 赵 营,赵光日,吴蕴瑜,等.LINC00536靶向miR-17-5p对卵巢癌细胞顺铂药物耐药性的影响[J].标记免疫分析与临床,2020,27(11):129-134.
[16] 张雪琼,任卫红,万思然,等.紫杉醇联合卡铂对复发上皮性卵巢癌妇女血清HE4、HK10及T细胞亚群水平的影响[J].贵州医药,2019,43(1):22-24.
[17] 韩 冰,张知洪,曹东林.卵巢癌患者血清HK10、CA125、HE4的表达水平及意义[J].实用癌症杂志,2020,35(12):63-65,69.
[18] 任 俊,柯重伟.奥沙利铂抗肿瘤及其耐药机制的研究进展[J].上海医药,2021,42(4):3-8.
[19] 王亚茹,邵 娟,刘新美.贝伐珠单抗联合TP方案治疗卵巢癌的临床研究[J].中国性科学,2020,29(12):61-64.
[20] 罗 纯.贝伐单抗联合托泊替康治疗铂耐药性卵巢癌对血清Smac及SMRP水平的影响[J].广西医科大学学报,2019,36(9):1488-1492.
[21] 祖逸峥,马少寒,李茹月,等.贝伐单抗联合白蛋白结合型紫杉醇治疗复发性卵巢癌临床疗效的Meta分析[J].宁夏医科大学学报,2021,277(10):1029-1035,1044.

相似文献/References:

[1]杨庆伟,梁海鹏△,陈小鹏,等.华蟾素胶囊联合多西他赛、奥沙利铂、替吉奥方案治疗晚期胃癌临床研究[J].陕西医学杂志,2020,49(7):884.[doi:DOI:10.3969/j.issn.10007377.2020.07.032]
　YANG Qingwei,LIANG Haipeng,CHEN Xiaopeng,et al.Clinical observation of huachansu capsules combined with chemotherapy in the treatment of advanced gastric cancer[J].,2020,49(1):884.[doi:DOI:10.3969/j.issn.10007377.2020.07.032]
[2]张晓微,杨宇慎,赵雪峰△.槐果碱联合奥沙利铂对裸鼠结肠癌肝转移抑制作用的实验研究*[J].陕西医学杂志,2020,49(11):1371.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.001]
　ZHANG Xiaowei,YANG Yushen,ZHAO Xuefeng..Inhibitory effect of sophocarpine combined with oxaliplatin on hepatic metastasis of colon cancer in nude mice[J].,2020,49(1):1371.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.001]
[3]裴彦江,戚 斌.术前替吉奥联合奥沙利铂新辅助化疗治疗SiewertⅡ型食管胃结合部腺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1420.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.024]
[4]屠佳佳,王利云,孙 波,等.长链非编码RNA F-box富含亮氨酸的重复蛋白19反义RNA 1调节微小RNA-342-3p/自噬相关蛋白10轴对结直肠癌细胞增殖、迁移和奥沙利铂耐药性的影响实验研究[J].陕西医学杂志,2024,(12):1604.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.004]
　TU Jiajia,WANG Liyun,SUN Bo,et al.Effects of lncRNA FBXL19-AS1 on proliferation,migration,and oxaliplatin resistance of colorectal cancer cells by regulating miR-342-3p/ATG10 axis[J].,2024,(1):1604.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.004]

备注/Memo

备注/Memo:
基金项目:西安市卫生健康委员会科研项目(2021QN02)
更新日期/Last Update: 2022-01-09